Tempus AI Study Shows Pre-Screening Panel Exceeds 80% Sensitivity Across 12 Lung Cancer Biomarkers
Bitget2026/10/19 12:37- Tempus AI announced study results showing its AI-enabled pre-screening panel could help identify advanced non-small cell lung cancer patients needing biomarker testing.
- The analysis covered 60,459 cases across 56,969 patients through a collaboration with Pfizer.
- Results were presented at the European Society for Medical Oncology Congress 2026 in Madrid.
- The panel analyzes routine pathology images to help prioritize diagnostic testing, potentially accelerating treatment decisions while preserving limited tumor tissue.
- The panel remains in development as a tool to guide subsequent testing, not replace established molecular or immunohistochemistry tests.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Shipping stocks fell 6.8% weekly, underperforming the market, while the tanker sector has surged 115% year-to-date.
The Capital Link Maritime Index fell by 6.8% last week, significantly underperforming the S&P 500. Despite the industry's total market capitalization shrinking by $6.5 billion, the tanker sector led the way with a 115% increase year-to-date, and trading activity surged sharply.
Strong earnings report can't stop sell-off! Credit concerns intensify as US bank stocks record longest losing streak since 2008
Although the financial reports released so far by some of the largest banks in the United States remain robust, U.S. bank stocks are currently experiencing their longest period of decline since the 2008 financial crisis.
3M (MMM.US) issues 3.16 million warrants to Amazon, expanding data center product cooperation
Shares of 3M rose after the company announced an expanded partnership with Amazon Data Center products.
Crypto prices
More
